Literature DB >> 29945958

Combined MR Imaging of Oxygen Consumption and Supply Reveals Tumor Hypoxia and Aggressiveness in Prostate Cancer Patients.

Therese Seierstad1, Heidi Lyng2, Tord Hompland3, Knut Håkon Hole1, Harald Bull Ragnum3,4, Eva-Katrine Aarnes3, Ljiljana Vlatkovic5, A Kathrine Lie5, Sebastian Patzke3, Bjørn Brennhovd6.   

Abstract

The established role of hypoxia-induced signaling in prostate cancer growth, metastasis, and response to treatment suggests that a method to image hypoxia in tumors could aid treatment decisions. Here, we present consumption and supply-based hypoxia (CSH) imaging, an approach that integrates images related to oxygen consumption and supply into a single image. This integration algorithm was developed in patients with prostate cancer receiving hypoxia marker pimonidazole prior to prostatectomy. We exploited the intravoxel incoherent motion (IVIM) signal in diagnostic diffusion-weighted (DW) magnetic resonance (MR) images to generate separate images of the apparent diffusion coefficient (ADC) and fractional blood volume (fBV). ADC and fBV correlated with cell density (CD) and blood vessel density (BVD) in histology and whole-mount sections from 35 patients, thus linking ADC to oxygen consumption and fBV to oxygen supply. Pixel-wise plots of ADC versus fBV were utilized to predict the hypoxia status of each pixel in a tumor and to visualize the predicted value in a single image. The hypoxic fraction (HFDWI) of CSH images correlated strongly (R2 = 0.66; n = 41) with pimonidazole immunoscore (HSPimo); this relationship was validated in a second pimonidazole cohort (R2 = 0.54; n = 54). We observed good agreement between CSH images and pimonidazole staining in whole-mount sections. HFDWI correlated with tumor stage and lymph node status, consistent with findings for HSPimo Moreover, CSH imaging could be applied on histologic CD and BVD images, demonstrating transferability to a histopathology assay. Thus, CSH represents a robust approach for hypoxia imaging in prostate cancer that could easily be translated into clinical practice.Significance: These findings present a novel imaging strategy that indirectly measures tumor hypoxia and has potential application in a wide variety of solid tumors and other imaging modalities.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/16/4774/F1.large.jpg Cancer Res; 78(16); 4774-85. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29945958     DOI: 10.1158/0008-5472.CAN-17-3806

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic 18F-FMISO PET for Head and Neck Cancer Radiotherapy.

Authors:  Daniela Thorwarth; Stefan Welz; David Mönnich; Christina Pfannenberg; Konstantin Nikolaou; Matthias Reimold; Christian La Fougère; Gerald Reischl; Paul-Stefan Mauz; Frank Paulsen; Markus Alber; Claus Belka; Daniel Zips
Journal:  J Nucl Med       Date:  2019-05-10       Impact factor: 10.057

2.  Let there be oxygen and T cells.

Authors:  Paul R Walker
Journal:  J Clin Invest       Date:  2018-10-15       Impact factor: 14.808

3.  Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth.

Authors:  Lifeng Yang; Tara TeSlaa; Serina Ng; Michel Nofal; Lin Wang; Taijin Lan; Xianfeng Zeng; Alexis Cowan; Matthew McBride; Wenyun Lu; Shawn Davidson; Gaoyang Liang; Tae Gyu Oh; Michael Downes; Ronald Evans; Daniel Von Hoff; Jessie Yanxiang Guo; Haiyong Han; Joshua D Rabinowitz
Journal:  Med (N Y)       Date:  2022-02-11

Review 4.  The future of MRI in radiation therapy: Challenges and opportunities for the MR community.

Authors:  Rosie J Goodburn; Marielle E P Philippens; Thierry L Lefebvre; Aly Khalifa; Tom Bruijnen; Joshua N Freedman; David E J Waddington; Eyesha Younus; Eric Aliotta; Gabriele Meliadò; Teo Stanescu; Wajiha Bano; Ali Fatemi-Ardekani; Andreas Wetscherek; Uwe Oelfke; Nico van den Berg; Ralph P Mason; Petra J van Houdt; James M Balter; Oliver J Gurney-Champion
Journal:  Magn Reson Med       Date:  2022-09-21       Impact factor: 3.737

5.  Longitudinal Correlations Between Intravoxel Incoherent Motion (IVIM) and Dynamic Contrast-Enhanced (DCE) MRI During Radiotherapy in Prostate Cancer Patients.

Authors:  Ernst S Kooreman; Vivian van Pelt; Marlies E Nowee; Floris Pos; Uulke A van der Heide; Petra J van Houdt
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

6.  Evaluation of HIF-1α Expression in a Rat Glioma Model Using Intravoxel Incoherent Motion and R2* Mapping.

Authors:  Dongdong Wang; Yiping Lu; Xuanxuan Li; Nan Mei; Pu-Yeh Wu; Daoying Geng; Hao Wu; Bo Yin
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

Review 7.  Background, applications and challenges of radiogenomics in genitourinary tumor.

Authors:  Longfei Liu; Xiaoping Yi; Can Lu; Yingxian Pang; Xiongbing Zu; Minfeng Chen; Xiao Guan
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

8.  Association analysis between quantitative MRI features and hypoxia-related genetic profiles in prostate cancer: a pilot study.

Authors:  Yu Sun; Scott Williams; David Byrne; Simon Keam; Hayley M Reynolds; Catherine Mitchell; Darren Wraith; Declan Murphy; Annette Haworth
Journal:  Br J Radiol       Date:  2019-07-30       Impact factor: 3.039

9.  Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity.

Authors:  Christina S Fjeldbo; Tord Hompland; Tiril Hillestad; Eva-Katrine Aarnes; Clara-Cecilie Günther; Gunnar B Kristensen; Eirik Malinen; Heidi Lyng
Journal:  EBioMedicine       Date:  2020-06-21       Impact factor: 8.143

10.  Refinement of an Established Procedure and Its Application for Identification of Hypoxia in Prostate Cancer Xenografts.

Authors:  Pernille B Elming; Thomas R Wittenborn; Morten Busk; Brita S Sørensen; Mathilde Borg Houlberg Thomsen; Trine Strandgaard; Lars Dyrskjøt; Steffen Nielsen; Michael R Horsman
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.